AR018107A1 - Pluralidad de particulas estables durante el almacenamiento de un tamano y forma definitivo - Google Patents

Pluralidad de particulas estables durante el almacenamiento de un tamano y forma definitivo

Info

Publication number
AR018107A1
AR018107A1 ARP990100728A ARP990100728A AR018107A1 AR 018107 A1 AR018107 A1 AR 018107A1 AR P990100728 A ARP990100728 A AR P990100728A AR P990100728 A ARP990100728 A AR P990100728A AR 018107 A1 AR018107 A1 AR 018107A1
Authority
AR
Argentina
Prior art keywords
particle
organic compound
solvent
group
size
Prior art date
Application number
ARP990100728A
Other languages
English (en)
Original Assignee
John Claude Savoir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21853984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR018107(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by John Claude Savoir filed Critical John Claude Savoir
Publication of AR018107A1 publication Critical patent/AR018107A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Abstract

Un método para efectuar la cristalizacion en estado solido de un compuesto orgánico molecular alotropico en una partícula de tamano y forma definidos, quecomprende: (i) exposicion de dicha partícula a una atmosfera saturada con un solvente para dichocompuesto orgánico; y (ii) recuperacion de dicha partícula, endihco compuesto orgánico en dicha partícula recuperada es de estructura cristalina uniforme, y dicha partícula recuperada ha retenido dicho tamano y forma.Dicha partícula se selecciona del grupo que integran: un solido liofilizado, una pastilla, y un implante. La forma preferida de dicha partícula es la de unamicroesferea de un diámetro de entre aproximadamente 1 y 1.000 micrones. La partícula se puede formar primeramente por fusion-congelacion de dicho compuestoorgánico para dar una microesfera. Dicho solvente se selecciona del grupo que integran: agua, etanol, acetona, ácido acético, tolueno, benceno y dichocompuesto orgánico es un agente farmacoterapéutico que exhibe polimorfismo, el cual puede ser, en esterol o un esteroide. Dicho esterol o esteroide seselecciona del grupo que integran: 17-beta-estradiol, estrogeno, testosterona, progesterona, colesterol, y mezclas de los mismos. La atmosfera se mantien a unatemperaturasuficiente para conseguir la vaporizacion de dicho solvente, pero por debajo del punto de fusion de dicho compuesto orgánico. La atmosfera semantiene a una temperatura suficiente para conseguir la vaporizacion de dicho solvente, pero por debajo delpunto de fusion de dicho compuesto orgánico. Lapartícula recuperada se almacena posteriormente en forma seca o en un medio acuoso, manteniendo dichos tamano y forma durante el almacenamiento en mediosacuosos por lo menos durante alrededor de un mes.Dicha partícula también comprende un aditivo seleccionado del grupo que integran; excipientes farmacéuticos,reguladores de pH, estabilizantes y combinaciones de los mismos y la forma cristalina deseada del compuesto orgánico alotropico es un hidrato.Dicho método esaplicado a una mezcla que contiene al menos un compuesto orgánico molecular alotropico, en donde dicha mezcla ha sido además congelada para dar lugar a una
ARP990100728A 1998-02-25 1999-02-23 Pluralidad de particulas estables durante el almacenamiento de un tamano y forma definitivo AR018107A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/030,388 US6287693B1 (en) 1998-02-25 1998-02-25 Stable shaped particles of crystalline organic compounds

Publications (1)

Publication Number Publication Date
AR018107A1 true AR018107A1 (es) 2001-10-31

Family

ID=21853984

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP990100728A AR018107A1 (es) 1998-02-25 1999-02-23 Pluralidad de particulas estables durante el almacenamiento de un tamano y forma definitivo
ARP100100844A AR077167A2 (es) 1998-02-25 2010-03-17 Metodo para realizar la cristalizacion en estado solido de particulas conformadas de compuestos organicos alotropicos
ARP100100845A AR077168A2 (es) 1998-02-25 2010-03-17 Particulas estables en almacenamiento de compuestos organicos cristalinos de forma definida

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP100100844A AR077167A2 (es) 1998-02-25 2010-03-17 Metodo para realizar la cristalizacion en estado solido de particulas conformadas de compuestos organicos alotropicos
ARP100100845A AR077168A2 (es) 1998-02-25 2010-03-17 Particulas estables en almacenamiento de compuestos organicos cristalinos de forma definida

Country Status (35)

Country Link
US (7) US6287693B1 (es)
EP (4) EP2319497B1 (es)
JP (2) JP4885357B2 (es)
KR (1) KR100726315B1 (es)
CN (2) CN1146407C (es)
AR (3) AR018107A1 (es)
AT (2) ATE427102T1 (es)
AU (1) AU747779B2 (es)
BR (1) BR9908156A (es)
CA (1) CA2319176C (es)
CL (1) CL2010001333A1 (es)
CY (1) CY1118522T1 (es)
CZ (1) CZ301042B6 (es)
DE (2) DE69940684D1 (es)
DK (3) DK1772141T3 (es)
EE (1) EE05019B1 (es)
ES (3) ES2609284T3 (es)
HK (2) HK1036017A1 (es)
HU (1) HUP0101271A3 (es)
ID (1) ID26523A (es)
IL (2) IL137970A0 (es)
MY (1) MY138375A (es)
NO (1) NO331804B1 (es)
NZ (1) NZ505987A (es)
PE (1) PE20000393A1 (es)
PL (1) PL196369B1 (es)
PT (1) PT2085075T (es)
RU (1) RU2225708C2 (es)
SA (1) SA99200098B1 (es)
TR (1) TR200002462T2 (es)
TW (1) TWI256308B (es)
UA (1) UA73470C2 (es)
UY (1) UY25404A1 (es)
WO (1) WO1999043304A1 (es)
ZA (1) ZA991058B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EA007120B8 (ru) 2002-05-16 2012-03-30 Тиботек Фармасьютикалз Лтд. Псевдополиморфные формы ингибитора вич-протеазы
US20040028746A1 (en) * 2002-08-06 2004-02-12 Sonke Svenson Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
EA018356B1 (ru) * 2003-06-13 2013-07-30 Джон Клод Савуар Микросферы эстрадиола и холестерина
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
CA2532874A1 (en) * 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
CA2547774A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
WO2005081825A2 (en) 2004-02-23 2005-09-09 Euro-Celtique S.A. Abuse resistance opioid transdermal delivery device
US20080200682A1 (en) * 2005-06-17 2008-08-21 Basf Aktiengesellschaft Process of Producing Bleach Boosters
MX2010010512A (es) * 2008-03-26 2010-11-09 Alltranz Inc Formulaciones transdermicas de agonistas y antagonistas-agonistas de opiato que impiden el abuso.
EP2272519A4 (en) * 2008-04-14 2011-04-27 Posi Visionary Solutions Llp METHOD AND PHARMACEUTICAL COMPOSITION FOR ACHIEVING THE PLASMA PROGESTERONE MIRRORS NECESSARY FOR VARIOUS THERAPEUTIC INDICATIONS
FR2939326B1 (fr) * 2008-12-10 2011-04-01 Univ Joseph Fourier Procede et dispositif de controle d'une cristallisation.
US9023390B2 (en) 2009-09-17 2015-05-05 Upsher-Smith Laboratories, Inc. Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
EP2548879B1 (en) * 2010-03-19 2015-12-09 Daiichi Sankyo Company, Limited Crystal of diamine derivative and method of producing same
KR101314126B1 (ko) 2011-03-11 2013-10-04 서울대학교산학협력단 다면체 형상의 약물 전달 시스템
US9351924B2 (en) 2011-03-11 2016-05-31 Snu R&Db Foundation Drug delivery system including laminated structure
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PL2782584T3 (pl) 2011-11-23 2021-12-13 Therapeuticsmd, Inc. Naturalne skojarzone hormonalne formulacje i terapie zastępcze
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EA035469B1 (ru) 2013-03-15 2020-06-22 Инсайт Холдингс Корпорейшн Трициклические гетероциклы как ингибиторы белков бэт
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
MX2016013851A (es) 2014-04-23 2017-07-14 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h) -onas como inhibidores de proteinas de bromodominio y extra terminal (bet).
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
ITUB20153652A1 (it) * 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
IL263824B2 (en) 2016-06-20 2023-10-01 Incyte Corp Crystals in solid form in the presence of an inhibitor
PL236889B1 (pl) * 2017-10-03 2021-02-22 Univ Warszawski Medyczny Nowa forma krystaliczna bezwodnego 17-β-estradiolu, sposób jej otrzymywania oraz kompozycja farmaceutyczna zawierająca nową formę krystaliczną bezwodnego 17-β-estradiolu i jej zastosowanie
EP3542786A1 (en) * 2018-03-21 2019-09-25 ITF Research Pharma, S.L.U. Progesterone intravaginal devices
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2447362A (en) 1945-11-01 1948-08-17 Rca Corp Production of crystals
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
US4230621A (en) * 1978-05-01 1980-10-28 E. R. Squibb & Sons, Inc. Steroid derivatives and their use in radioimmunoassays
DE2843963A1 (de) * 1978-10-09 1980-04-24 Merck Patent Gmbh Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
JPS5799562A (en) 1980-12-12 1982-06-21 Nippon Shinyaku Co Ltd Preparation of microcrystal
DE3049196A1 (de) 1980-12-24 1982-07-29 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von granulaten aus organischen in form einer schmelze vorliegenden stoffen
US4447426A (en) * 1982-01-18 1984-05-08 E. R. Squibb & Sons, Inc. Steroid monohydrates, formulations containing same and method
JPS58143832A (ja) 1982-02-22 1983-08-26 Yoshiaki Kawashima 結晶性化学物質の球状化再結晶法
DE3213025C2 (de) 1982-04-02 1997-06-12 Fischer Karl Ind Gmbh Verfahren zur Nachkondensation von Polykondensaten
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
JPH0714625B2 (ja) 1987-03-30 1995-02-22 呉羽化学工業株式会社 高結晶化ポリアリ−レンチオエ−テル成形物
US4897307A (en) 1987-08-11 1990-01-30 The Dow Chemical Company Process for the solvent-induced crystallization of amorphous poly(etheretherketone)-type polymers and the article formed thereby
US4948871A (en) 1987-09-28 1990-08-14 Asahi Kasei Kogyo Kabushiki Kaisha Method for producing a crystallized aromatic polycarbonate, and a crystallized aromatic polycarbonate obtained thereby
US4919899A (en) 1988-02-29 1990-04-24 Herrmann Frederick T Crystal growth apparatus
YU120988A (en) * 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
IT1230566B (it) 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
US5360478A (en) 1989-10-16 1994-11-01 Phasex Corporation Gas anti-solvent recrystallization process
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
JPH04305226A (ja) 1991-01-25 1992-10-28 Senichi Masuda ガス中窒素酸化物の低減方法
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5391810A (en) 1991-05-23 1995-02-21 Ajinomoto Co., Inc. Method of crystallizing α-L-aspartyl-L-phenylalanine methyl ester
DE4130173A1 (de) 1991-09-11 1993-03-18 Bayer Ag Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters
DE4218929C1 (es) 1992-06-10 1993-09-09 Deutsche Bundesbahn, Vertreten Durch Das Bundesbahn-Zentralamt Minden (Westf.), 4950 Minden, De
US5290913A (en) 1992-10-08 1994-03-01 Carrier Vibrating Equipment, Inc. Method and apparatus for the heat treatment of material
US5558678A (en) 1992-11-13 1996-09-24 Karl Fischer Industrieanlagen Gmbh Process and apparatus for continuous crystallization of plastic granules
US5686092A (en) 1992-11-24 1997-11-11 Alkermes Controlled Therapeutics Inc. Ii Growth promoters for animals
WO1994020116A1 (en) * 1993-03-10 1994-09-15 University Of Alabama Research Foundation Artificial primers for glycogen synthesis
US5409605A (en) * 1993-08-05 1995-04-25 Chemical Lime Company Apparatus and method for treating waste sludge
JPH0757558A (ja) * 1993-08-09 1995-03-03 Showa Electric Wire & Cable Co Ltd 耐熱絶縁電線
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5849651A (en) * 1995-06-01 1998-12-15 Kabushiki Kaisha Toshiba Reversible thermal recording medium
JPH0957558A (ja) * 1995-08-18 1997-03-04 Nabeya Iron & Tool Works Ltd スライド装置
JPH09227558A (ja) * 1996-02-28 1997-09-02 Fujisawa Pharmaceut Co Ltd チアゾール化合物の安定な結晶およびその製造方法
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
JP2000143832A (ja) 1998-11-10 2000-05-26 Toppan Printing Co Ltd 高剛性を有するフィルムまたはシート

Also Published As

Publication number Publication date
CN1524608A (zh) 2004-09-01
CY1118522T1 (el) 2017-07-12
TWI256308B (en) 2006-06-11
HUP0101271A2 (hu) 2001-09-28
HK1036017A1 (en) 2001-12-21
KR20010034540A (ko) 2001-04-25
US6287693B1 (en) 2001-09-11
NZ505987A (en) 2003-07-25
NO331804B1 (no) 2012-04-10
CA2319176A1 (en) 1999-09-02
EE05019B1 (et) 2008-06-16
SA99200098B1 (ar) 2006-04-26
CN1291887A (zh) 2001-04-18
EE200000492A (et) 2002-02-15
CA2319176C (en) 2007-09-11
UA73470C2 (uk) 2005-08-15
ZA991058B (en) 1999-08-11
CZ301042B6 (cs) 2009-10-21
CL2010001333A1 (es) 2011-04-25
DK2085075T3 (en) 2017-01-23
NO20004241D0 (no) 2000-08-24
US7427413B2 (en) 2008-09-23
EP2085075A1 (en) 2009-08-05
TR200002462T2 (tr) 2000-11-21
PL196369B1 (pl) 2007-12-31
RU2225708C2 (ru) 2004-03-20
DK1772141T3 (da) 2009-07-20
ATE345779T1 (de) 2006-12-15
AR077167A2 (es) 2011-08-10
AU747779B2 (en) 2002-05-23
WO1999043304A1 (en) 1999-09-02
EP2319497A1 (en) 2011-05-11
US6528094B1 (en) 2003-03-04
US6638536B2 (en) 2003-10-28
CN100528140C (zh) 2009-08-19
DK1056444T3 (da) 2007-03-12
EP1772141B1 (en) 2009-04-01
ES2324366T3 (es) 2009-08-05
PT2085075T (pt) 2017-01-04
AU2293699A (en) 1999-09-15
JP2011241220A (ja) 2011-12-01
US20030147964A1 (en) 2003-08-07
IL137970A (en) 2006-10-05
CN1146407C (zh) 2004-04-21
ES2609284T3 (es) 2017-04-19
ATE427102T1 (de) 2009-04-15
JP4885357B2 (ja) 2012-02-29
EP2319497B1 (en) 2012-08-22
AR077168A2 (es) 2011-08-10
EP2085075B1 (en) 2016-09-28
US6537580B1 (en) 2003-03-25
PE20000393A1 (es) 2000-05-04
US20020168395A1 (en) 2002-11-14
UY25404A1 (es) 1999-05-14
US6663895B2 (en) 2003-12-16
DE69940684D1 (de) 2009-05-14
JP2002504507A (ja) 2002-02-12
HUP0101271A3 (en) 2002-10-28
EP1056444A1 (en) 2000-12-06
ES2275334T3 (es) 2007-06-01
US20030191101A1 (en) 2003-10-09
DE69934099D1 (de) 2007-01-04
HK1155384A1 (en) 2012-05-18
MY138375A (en) 2009-05-29
US6737081B2 (en) 2004-05-18
US20040166164A1 (en) 2004-08-26
DE69934099T2 (de) 2007-06-21
IL137970A0 (en) 2001-10-31
CZ20003047A3 (cs) 2000-11-15
ID26523A (id) 2001-01-11
BR9908156A (pt) 2000-10-31
EP1772141A1 (en) 2007-04-11
PL343170A1 (en) 2001-07-30
KR100726315B1 (ko) 2007-06-11
EP1056444B1 (en) 2006-11-22
NO20004241L (no) 2000-08-24

Similar Documents

Publication Publication Date Title
AR018107A1 (es) Pluralidad de particulas estables durante el almacenamiento de un tamano y forma definitivo
CO5011099A1 (es) Formulaciones en polvo en estado cristalino estable
JPS59137790A (ja) 潜熱貯蔵供給方法および装置
CO5560540A2 (es) Composicion cristalina que contiene escitalopram
RU2000124327A (ru) Стабильные частицы определенной формы кристаллических органических соединений
ATE77946T1 (de) Injizierbares langwirkendes mikroteilchenpr|parat zur verabreichung entzuendungshemmender mittel.
JP2005041716A (ja) ゲスト分子の単層カーボンナノチューブへの内方のためのナノ抽出法ならびにナノ凝縮法
KR830007671A (ko) 결정성 1,1-디옥소페니실라노일옥시메틸 6-(D-α-아미노-α-페닐아세트아미도)페니실라네이트 토실레이트 수화물의 제조방법
HUP9903454A2 (hu) Cefditoren-pivoxil kristályos formája, és eljárás annak előállítására
ES2173268T3 (es) Procedimiento de recuperacion de un compuesto organico contenido en soluciones.
Khan et al. Preparation, characterization, and evaluation of physicochemical properties of different crystalline forms of ibuprofen
Davey et al. Purification of molecular mixtures below the eutectic by emulsion crystallization
KR900013950A (ko) (7α,17α)-17-히드록시-7-메틸-19-노르-17-프레근-5(10)-엔-20-인-3-온 화합물 및 약학적 담체를 함유한 약학적 조성물
ES2625931T3 (es) Proceso para la preparación de sal de sodio de ibuprofeno de diferentes tamaños de partícula
KR910000788A (ko) 쉽게 용해할수 있는 결정성 α-L-아스파르틸-L-페닐알라닌메틸 에스테르의 제조방법
JP2739026B2 (ja) 蓄熱用マイクロカプセルおよびその製造方法
Wright et al. Biocytin, a naturally-occurring complex of biotin
Shiraiwa et al. Optical resolution by replacing crystallization of DL-threonine
CN107974713B (zh) 一种一维二肽单晶及其在毛细管内的自组装制备方法和解组装方法
Arias et al. Thermal Study of Different Omeprazole-Γ-CD CO-Ground Systems
PT87907B (pt) Processo de preparacao do acido 3-(3-piridil)-1h-3h-pirrolo{1,2-c}-7-tiazolocarboxilico dextrogiro
Diallo et al. Etude en spectrographie infrarouge et de résonance magnétique nucléaire de l'hydrolyse et de l'acidolyse d'un amido-phosphite bicyclique contraint
JP3012085B2 (ja) 固体物質の組織中に埋没されている有機溶剤を除去する方法
van Winden DANIEL, S.:" Les oeuvres de Philon d'Alexandrie", 24:" De specialibus legibus", I, II (Book Review)
KR20010002173A (ko) β-ＨＭＸ의 재결정 방법

Legal Events

Date Code Title Description
FC Refusal